Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Adjuvant immunotherapy improves melanoma outcomes

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.10.16
Views: 1377

Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France

Prof Eggermont presents, at a press conference at ESMO 2016, the finding that ipilimumab as adjuvant therapy significantly improve overall survival in patients with high risk stage III melanoma, according to the Phase III trial.

Watch the interview or read the news story for more.


· ESMO 2016

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation